Percutaneous lead dysfunction in the HeartMate II left ventricular assist device.

BACKGROUND: The incidence of percutaneous lead failure among patients supported with a HeartMate II left ventricular assist device is unknown. METHODS: All HeartMate II left ventricular assist device driveline dysfunctions reported to Thoratec Corporation were retrospectively reviewed. The location and severity of driveline failures and their association with adverse clinical outcomes were examined. Also, the effect of design modifications was evaluated. RESULTS: Between 2004 and October 2012, 12,969 HeartMate II pumps were implanted worldwide. The incidence of percutaneous lead dysfunction was 1,418 events occurring in 1,198 pumps (9.2% of pumps) over a cumulative support period of 13,932 patient-years (maximum, 8 years). Lead failure was mostly in the externalized part of the cable (87.2%). Lead dysfunction was managed by clamshell reinforcement of the external connector strain relief or by tape or silicone cable reinforcement in 76% of cases. Mortality or significant morbidity, including pump exchange or urgent transplant, or more complex cable repair occurred in 2.3% of all implanted pumps. The cumulative incidence of lead failures leading to major adverse clinical events has decreased with two lead design revisions: at 18 months postimplantation, the incidence was 6.2%±1.2% for the original design versus 2.2%±0.5% for the latest design change introduced in 2010 (log-rank p<0.001). CONCLUSIONS: Lead failures remain an important factor in the durability of left ventricular assist devices during long-term support. Most lead failures in the HeartMate II occurred in the externalized portion of the driveline, suggesting lead fatigue. The incidence of both internal and external lead failures has diminished since 2004 with improvements in lead design.

Periarteritis in lung from a continuous-flow right ventricular assist device: role of the local Renin-Angiotensin system.

BACKGROUND: We previously reported renal arterial periarteritis after implantation of a continuous-flow left ventricular assist device in calves. The purpose of the present study was to investigate whether the same periarteritis changes occur in the intrapulmonary arteries after implantation of a continuous-flow right ventricular assist device (CFRVAD) in calves and to determine the mechanism of those histologic changes. METHODS: Ten calves were implanted with a CFRVAD for 29 ± 7 days, and we compared pulmonary artery samples and hemodynamic data before and after CFRVAD implantation prospectively. RESULTS: After implantation, the pulsatility index (pulmonary arterial pulse pressure/pulmonary arterial mean pressure) significantly decreased (0.88 ± 0.40 before vs 0.51 ± 0.22 after; p < 0.05), with severe periarteritis of the intrapulmonary arteries in all animals. Periarterial pathology included hyperplasia and inflammatory cell infiltration. The number of inflammatory cells positive for the angiotensin II type 1 receptor was significantly higher after implantation (7.8 ± 6.5 pre-CFRVAD vs 313.2 ± 145.2 at autopsy; p < 0.01). Serum angiotensin-converting enzyme activity significantly decreased after implantation from 100% to 49.7 ± 17.7% at week 1 (p = 0.01). Tissue levels of angiotensin-converting enzyme also demonstrated a significant reduction (0.381 ± 0.232 before implantation vs 0.123 ± 0.096 at autopsy; p = 0.043). CONCLUSIONS: Periarteritis occurred in the intrapulmonary arteries of calves after CFRVAD implantation. The local renin-angiotensin system (not the angiotensin-converting enzyme pathway) plays an important role in such changes.

Cardiac autonomic nerve stimulation in the treatment of heart failure.

Research on the therapeutic modulation of cardiac autonomic tone by electrical stimulation has yielded encouraging early clinical results. Vagus nerve stimulation has reduced the rates of morbidity and sudden death from heart failure, but therapeutic vagus nerve stimulation is limited by side effects of hypotension and bradycardia. Sympathetic nerve stimulation that has been implemented in the experiment may exacerbate the sympathetic-dominated autonomic imbalance. In contrast, concurrent stimulation of both sympathetic and parasympathetic cardiac nerves increases myocardial contractility without increasing heart rate. This review assesses the current state of electrical stimulation of the cardiac autonomic nervous system to treat heart failure.

Mechanical circulatory support for heart failure: past, present and a look at the future.

Heart transplantation remains the gold standard for long-term cardiac replacement, but a shortage of donor organs will always limit this option. For both transplant-eligible and noneligible patients, advances in mechanical circulatory support have revolutionized the options for the management of end-stage heart failure, and this technology continues to bring us closer to a true alternative to heart transplantation. This review provides a perspective on the past, present and future of mechanical circulatory support and addresses the changes in technology, patient selection and management strategies needed to have this therapy fully embraced by the heart failure community, and perhaps replace heart transplantation either as the therapy of choice or as a strategy by which to delay transplantation in younger patients.

Overview of current sutureless and transcatheter mitral valve replacement technology.

Mitral valve (MV) regurgitation is the most prevalent form of heart valve disease. As it comes to surgical repair or replacement of the diseased valves, the procedure has been established as safe and effective; however, its invasiveness still carries considerable risk of significant morbidity and mortality. With aging comes increased MV dysfunction, and thus minimally invasive technology is rapidly evolving to meet the challenges of older patients' preoperative comorbidities and risks associated with surgery. In comparison, in high-risk patients with aortic stenosis, percutaneous transcatheter technologies offer a viable alternative to surgery; however, catheter-based procedures for MV disease are limited only to repair. MV surgeries have limitations and carry the potential for serious complications in high-risk elderly patients. A fast, reliable sutureless or catheter-based means of MV replacement is needed. Although transcatheter devices are still only in preclinical testing or developmental stages, the authors here review various sutureless MV and transcatheter-based concepts and devices for MV replacement.

Preload sensitivity in cardiac assist devices.

With implantable cardiac assist devices increasingly proving their effectiveness as therapeutic options for end-stage heart failure, it is important for clinicians to understand the unique physiology of device-assisted circulation. Preload sensitivity as it relates to cardiac assist devices is derived from the Frank-Starling relationship between human ventricular filling pressures and ventricular stroke volume. In this review, we stratify the preload sensitivity of 17 implantable cardiac assist devices relative to the native heart and discuss the effect of preload sensitivity on left ventricular volume unloading, levels of cardiac support, and the future development of continuous-flow total artificial heart technology.

Axial and centrifugal continuous-flow rotary pumps: a translation from pump mechanics to clinical practice.

The recent success of continuous-flow circulatory support devices has led to the growing acceptance of these devices as a viable therapeutic option for end-stage heart failure patients who are not responsive to current pharmacologic and electrophysiologic therapies. This article defines and clarifies the major classification of these pumps as axial or centrifugal continuous-flow devices by discussing the difference in their inherent mechanics and describing how these features translate clinically to pump selection and patient management issues. Axial vs centrifugal pump and bearing design, theory of operation, hydrodynamic performance, and current vs flow relationships are discussed. A review of axial vs centrifugal physiology, pre-load and after-load sensitivity, flow pulsatility, and issues related to automatic physiologic control and suction prevention algorithms is offered. Reliability and biocompatibility of the two types of pumps are reviewed from the perspectives of mechanical wear, implant life, hemolysis, and pump deposition. Finally, a glimpse into the future of continuous-flow technologies is presented.

Effects of percutaneous stimulation of both sympathetic and parasympathetic cardiac autonomic nerves on cardiac function in dogs.

OBJECTIVE: Augmentation of left ventricular (LV) contractility and heart rate (HR) by sympathetic nerve stimulation and amelioration of heart failure by vagal nerve stimulation has been reported. However, the effects of concomitant electrical stimulation of both sympathetic and parasympathetic cardiac nerves in tissues such as those of the cardiac plexus remain unclear. This study sought to assess acute changes in cardiac function and hemodynamics in response to endovascular cardiac plexus stimulation (CPS). METHODS: Twelve dogs received endovascular CPS via a bipolar catheter within the right pulmonary artery. Stimulation frequency (20 Hz) and pulse width (4 milliseconds) were fixed; voltage varied (range, 15-60 V). RESULTS: Results fell into three categories: 1, no response (n = 4); 2, an increase in systemic arterial pressure that was dependent on electrode placement (n = 4); and 3, a very reproducible and stable increase in aortic pressure (n = 4). In the third group, mean systolic aortic pressures, maximum value of the first derivative of LV pressure, and LV stroke work increased with stimulation (P < 0.02 for all parameters) as did cardiac output, end-systolic elastance, and preload recruitable stroke work (P = 0.03). Systemic and pulmonary vascular resistance, central venous pressure, pulmonary arterial pressure, and HR remained unchanged (P > 0.05). CONCLUSIONS: In contrast to conventional inotropic agents, endovascular CPS induced significant and selective increases in LV contractility without increasing HR. Efforts to optimize electrode placement and fixation will improve the reproducibility of endovascular CPS treatment.

Effect of epivascular cardiac autonomic nerve stimulation on cardiac function.

BACKGROUND: The cardiac plexus contains sympathetic and parasympathetic cardiac nerves. Our goal was to assess the hemodynamic and functional effects of stimulating the cardiac autonomic nervous system (CANS) at the epivascular surfaces of the cardiac plexus. Although CANS therapy to modulate cardiovascular function has drawn widespread interest, research has focused only on stimulating parasympathetic or sympathetic nerves, not both at once. METHODS: Using general anesthesia and an open-chest surgical procedure, 12 dogs received epivascular stimulation of the cardiac plexus. A bipolar electrode was placed between the right pulmonary artery (PA) and the ascending aorta, with the stimulation frequency/pulse width held constant (20 Hz/4 ms) and the voltage varied (10-50 V). Left ventricular (LV) pressure-volume loops and hemodynamic data were recorded with and without stimulation. RESULTS: In all dogs, aortic and LV systolic pressures, maximum rate of change of LV pressure, and LV stroke work increased (p<0.0001), as did cardiac output (2.9±1.0-0.4±1.0 L/min; p=0.001), end-systolic elastance (1.2±0.4-1.5±0.5 mm Hg/mL; p=0.0001), preload recruitable stroke work (30.1±11.0-39.3±7.8 mm Hg; p=0.003), and LV ejection fraction (p=0.012). Systemic vascular resistance increased slightly (p=0.04), and pulmonary vascular resistance decreased (p=0.01). Mean heart rate and pulmonary arterial, central venous, and left atrial pressures remained unchanged (p>0.1). CONCLUSIONS: In contrast to inotropic drugs, epivascular CANS stimulation induced a significant and selective increase in LV contractility with no increase in heart rate.

Implantable continuous-flow right ventricular assist device: lessons learned in the development of a cleveland clinic device.

Although the need for right ventricular assist device (RVAD) support for right ventricular failure after the implantation of a continuous-flow left ventricular assist device has decreased, right ventricular failure still occurs in as many as 44% of patients after continuous-flow left ventricular assist device insertion. Cleveland Clinic's DexAide continuous-flow RVAD was implanted in 34 calves during the course of its development. This review discusses lessons learned in the design and development of an implantable continuous-flow RVAD that are drawn from the results of these in vivo studies, our clinical experience with RVAD support, and a review of previously published reports on clinical RVAD use.

Hemodynamic differences between the awake and anesthetized conditions in normal calves.

There is insufficient information in the literature about baseline circulatory parameters in normal calves in the anesthetized versus postoperative awake conditions under which a large volume of medical research is conducted. Eleven calves (mean body weight, 78.1 ± 14.3 kg) were implanted with a flow probe and fluid-filled pressure lines to measure cardiac output (CO), aortic (AoP), central venous (CVP), pulmonary arterial (PAP), and left atrial pressures (LAP). Systemic (SVR) and pulmonary vascular resistance (PVR) were also calculated. We obtained the above hemodynamic data (n = 11) and epicardial echocardiography (n = 7) during open-chest surgery under isoflurane anesthesia. After full recovery from surgery, animals were evaluated in the awake condition on postoperative days 6-9 using transthoracic echocardiography (n = 7) and the hemodynamic monitoring lines and probes noted (n = 11). CO, AoP, and PAP levels in the anesthetized condition were significantly lower than in the awake condition. Other hemodynamic parameters (CVP, LAP, SVR, and PVR) were not significantly different. In conclusion, data from this study quantify changes in CO, AoP, and PAP in anesthetized calves that may affect the hemodynamic response to experimental therapeutics such as new cardiac assist devices, prosthetic valves, and surgical interventions. Our study also provides baseline data for the translation of the hemodynamic data obtained in acute in vivo calf studies to that of an awake subject.

Transcatheter heart valve with variable geometric configuration: in vitro evaluation.

Clinically, the current transcatheter aortic valve (TAV) technology has shown a propensity for paravalvular leakage; studies have correlated this flaw to increased calcification at the implantation site and with nonideal geometry of the stented valve. The present study evaluated the hydrodynamics of different geometric configurations, in particular the intravalvular considerations. Three TAV devices were made to create a representative, size 26 mm TAV. Hydrodynamics were assessed using a pulse duplicator. The geometries tested were composed of the nominal, elliptical, triangular, and undersized shapes; along with half-constriction, a conformation in which only a portion of the stent was constrained. The TAVs were assessed for transvalvular pressure gradient (TVG), effective orifice area (EOA), and regurgitant fraction. The nominal-sized shape posed a larger TVG (6.2 ± 0.3 mm Hg) than other configurations (P < 0.001) except the undersized valves. EOA of the nominal sized TAV (1.7 ± 0.1 cm(2) ) was smaller than that of the triangular and half-elliptical versions (P < 0.001). The half- and full-undersized geometries had EOAs smaller than the nominal type (P < 0.001). Nominal shape had smaller regurgitation (6.7 ± 1.4%) than all configurations (P < 0.001) except for the half-undersized (4.0 ± 0.7, P < 0.001) with no statistically significant difference from the full-undersized (6.8 ± 1.3, P = 0.724). The testing of variable geometries showed significant differences from the nominal geometry with respect to TVG, EOA, and regurgitant fraction. In particular, many of these nonideal configurations demonstrated an increased intravalvular regurgitation.

Performance of bioprosthetic valves after glycerol dehydration, ethylene oxide sterilization, and rehydration.

OBJECTIVE: : Most commercially available bioprosthetic valves are stored in an aldehyde solution. We report a new alternative method: Self-expanding valves composed of dehydrated tissues with a high glycerin:water ratio can be collapsed into specially designed sheaths prior to sterilization for ease of delivery and storage. MATERIALS AND METHODS: : Changes in tissue dimension of five samples of bovine pericardium were evaluated from baseline after glycerol treatment, air-drying, ethylene oxide (EtO) sterilization, and rehydration with water. Three valves fabricated from glutaraldehyde cross-linked tissues, including porcine pericardial tissue, bovine pericardial tissue, and porcine aortic valve, were dehydrated through a proprietary glycerin-based process, collapsed, placed within a catheter, EtO sterilized, stored for up to 212 days, and rehydrated with water. These valves were characterized in a mock circulation by mounting them at the inlet portion of a pneumatic pump before dehydration and after rehydration to evaluate the effects of dehydration and rehydration on the valve performance. RESULTS: : Tissues treated with glycerol solution showed no significant changes in dimension from baseline after glycerol treatment, air-drying, EtO sterilization, and rehydration with water. In all the valves, pump flows reached the maximum output capacity of the pneumatic pump after rehydration without an increase in filling pressures as compared with those before dehydration. CONCLUSIONS: : This method for storing collapsible bioprosthetic valves using a proprietary glycerin-based process demonstrated excellent valve performance.

Performance of extracorporeally adjustable ventricular assist device inflow cannula.

PURPOSE: This study evaluated the feasibility and efficacy of a newly developed adjustable left ventricular assist device inflow cannula in a short-term calf model. DESCRIPTION: In this inflow cannula, the angle between the cannula body and the inflow cannula tip can be altered extracorporeally by manipulating 2 externalized cables connected to the cannula. The cannula tip is adjustable in any plane to a maximum of ±15 degrees. EVALUATION: After initial prototyping in 4 calf cadavers, a Cleveland Heart left ventricular assist device was implanted with the adjustable inflow cannula placed in the left ventricular apex and the outlet to the descending aorta. Under hypovolemic conditions, the angle of the cannula tip could be changed to induce varying degrees of ventricular suction and then eliminate it, as evidenced by recorded pump and native left ventricular flows. Epicardial echocardiography and fluoroscopy in the closed-chest condition documented extracorporeal adjustments of the inflow cannula position. CONCLUSIONS: This extracorporeally adjustable inflow cannula was effective in preventing or controlling left ventricular suction.

Speed modulation of the continuous-flow total artificial heart to simulate a physiologic arterial pressure waveform.

This study demonstrated the concept of using speed modulation in a continuous-flow total artificial heart (CFTAH) to shape arterial pressure waveforms and to adjust pressure pulsatility. A programmable function generator was used to determine the optimum pulsatile speed profile. Three speed profiles [sinusoidal, rectangular, and optimized (a profile optimized for generation of a physiologic arterial pressure waveform)] were evaluated using the CFTAH mock circulatory loop. Hemodynamic parameters were recorded at average pump speeds of 2,700 rpm and a modulation cycle of 60 beats per minute. The effects of varying physiologically relevant vascular resistance and lumped compliance on the hemodynamics were assessed. The feasibility of using speed modulation to manipulate systemic arterial pressure waveforms, including a physiologic pressure waveform, was demonstrated in vitro. The additional pump power consumption needed to generate a physiologic pulsatile pressure was 16.2% of the power consumption in nonpulsatile continuous-flow mode. The induced pressure waveforms and pulse pressure were shown to be very responsive to changes in both systemic vascular resistance and arterial compliance. This system also allowed pulsatile pulmonary arterial waveform. Speed modulation in the CFTAH could enable physicians to obtain desired pressure waveforms by simple manual adjustment of speed control input waveforms.

In vivo biocompatibility evaluation of a new resilient, hard-carbon, thin-film coating for ventricular assist devices.

The purpose of this study was to evaluate in vivo the biocompatibility of BioMedFlex (BMF), a new resilient, hard-carbon, thin-film coating, as a blood journal bearing material in Cleveland Heart's (Charlotte, NC, USA) continuous-flow right and left ventricular assist devices (RVADs and LVADs). BMF was applied to RVAD rotating assemblies or both rotating and stator assemblies in three chronic bovine studies. In one case, an LVAD with a BMF-coated stator was also implanted. Cases 1 and 3 were electively terminated at 18 and 29 days, respectively, with average measured pump flows of 4.9 L/min (RVAD) in Case 1 and 5.7 L/min (RVAD) plus 5.7 L/min (LVAD) in Case 3. Case 2 was terminated prematurely after 9 days because of sepsis. The sepsis, combined with running the pump at minimum speed (2000 rpm), presented a worst-case biocompatibility challenge. Postexplant evaluation of the blood-contacting journal bearing surfaces showed no biologic deposition in any of the four pumps. Thrombus inside the RVAD inlet cannula in Case 3 is believed to be the origin of a nonadherent thrombus wrapped around one of the primary impeller blades. In conclusion, we demonstrated that BMF coatings can provide good biocompatibility in the journal bearing for ventricular assist devices.

In vivo evaluation of zirconia ceramic in the DexAide right ventricular assist device journal bearing.

Zirconia is a ceramic with material properties ideal for journal bearing applications. The purpose of this study was to evaluate the use of zirconium oxide (zirconia) as a blood journal bearing material in the DexAide right ventricular assist device. Zirconia ceramic was used instead of titanium to manufacture the DexAide stator housing without changing the stator geometry or the remaining pump hardware components. Pump hydraulic performance, journal bearing reliability, biocompatibility, and motor efficiency data of the zirconia stator were evaluated in six chronic bovine experiments for 14-91 days and compared with data from chronic experiments using the titanium stator. Pump performance data including average in vivo pump flows and speeds using a zirconia stator showed no statistically significant difference to the average values for 16 prior titanium stator in vivo studies, with the exception of a 19% reduction in power consumption. Indices of hemolysis were comparable for both stator types. Results of coagulation assays and platelet aggregation tests for the zirconia stator implants showed no device-induced increase in platelet activation. Postexplant evaluation of the zirconia journal bearing surfaces showed no biologic deposition in any of the implants. In conclusion, zirconia ceramic can be used as a hemocompatible material to improve motor efficiency while maintaining hydraulic performance in a blood journal bearing application.

Introduction of fixed-flow mode in the DexAide right ventricular assist device.

BACKGROUND: Although some continuous-flow left ventricular assist device algorithms have been created to respond to varying patient physiology, very little research has been conducted on control of right ventricular support in uni- or biventricular application. The purpose of this study was to develop and evaluate a simple and reliable fixed-flow algorithm for the DexAide right ventricular assist device (RVAD). This algorithm automatically adjusts speed to maintain a target flow while preventing ventricular suction when a requested target flow exceeds available tricuspid flow. METHODS: Fixed-flow control mode was evaluated in 17 DexAide RVAD long-term bovine studies, with a duration ranging from 14 to 90 days (33 +/- 24 days). Targeted fixed-flow levels ranged from 4.0 to 6.5 liters/min. Data were monitored on an hourly basis. Pump-flow data were also recorded on a weekly basis to document the speed increment required to increase pump flow from 5 to 8 liters/min at 0.5-liter/min increments. RESULTS: The fixed-flow control mode was evaluated for a total duration of 5,283 hours without complications related to pump flow or left/right circulation imbalance. The pump speed varied between 2,000 and 3,220 rpm to maintain the flow constant at each target level. The average absolute mismatch between the target flow and measured flow was 0.6 +/- 0.5 liter/min. CONCLUSIONS: Fixed-flow control mode with a pre-determined maximum automatic pump speed can be used safely and effectively in the DexAide RVAD. It can provide target flows by adjusting the pump speed while monitoring pump-flow response to automatic speed increment requests.

Use of zirconia ceramic in the DexAide right ventricular assist device journal bearing.

Our aim was to evaluate the potential use of zirconium oxide (zirconia) as a blood journal bearing material in the DexAide right ventricular assist device. The DexAide titanium stator was replaced by a zirconia stator in several blood pump builds, without changing the remaining pump hardware components. In vitro pump performance and efficiency were evaluated at a predetermined pump speed and flow. Motor power consumption decreased by 20%, and DexAide battery life was extended to over 12 h on two fully charged batteries. The zirconia stator was also successfully evaluated in a severe start/stop test pre- and postexposure of the zirconia to accelerated simulated biologic aging. This study's outcomes indicated the advantages of zirconia as an alternate journal bearing material for the DexAide device.

A pilot study for inducing chronic heart failure in calves by means of oral monensin.

INTRODUCTION: Heart failure remains a major cause of mortality in the United States, despite advancing technologies, newer methods of treatment, and novel devices. To evaluate such novel devices, a large-animal model of chronic heart failure is critical in carrying out preclinical animal studies. METHODS: We evaluated the efficacy of oral monensin in inducing stable heart failure in five Jersey calves. Various doses of monensin were administered. Hemodynamics, pressure-volume loops, echocardiographic measurements, extent of tissue perfusion, and histopathologic data were recorded before and after induction of heart failure. RESULTS: Responses were variable in the animals. One experiment showed a significant decrease in cardiac output within one week, associated with simultaneous increases in left atrial pressure, central venous pressure, and mean pulmonary artery pressure. Left ventricular pressure-volume loops showed that the slope of the end-systolic pressure-volume relation decreased markedly between the baseline and terminal study, suggesting a decrease in contractility. Echocardiographic studies indicated a decrease in ejection fraction. Histopathologic analysis in cardiac tissue showed extensive fibrosis and necrosis. CONCLUSION: We demonstrated the feasibility of inducing and maintaining severe yet stable heart failure for up to 3 weeks in a calf model by administration of oral monensin.